InteliSpark client, Infinifluidics, Inc., wins a phase I SBIR (Small Business Innovation Research) grant from the National Science Foundation to create a portable, scalable, reproducible, platform for on-demand injectable drug delivery systems. These systems will not require any additional adjustment by the user and will be ready to be used as soon as they are connected.
Drug shortages are a growing public health issue in the United States with manufacturing problems as a main contributor to these shortages. Treatment delays leave many patients in a vulnerable or even dangerous state. To meet the needs of patients, healthcare providers, facilities, and pharmaceutical industries, technological innovation in manufacturing is more important than ever.
Infinifluidics, a startup spun out of the University of Pennsylvania, is developing on-demand injectable drug delivery systems to meet this market need in treating diseases such as cancer and cardiovascular disease. In this phase I project, Dr. Sagar Yadavali, CEO of Infinifluidics, will manage and oversee the development of injectable drug delivery systems at industrial scale on a portable chip, combining microfluidics with semiconductor technology.
The proposed technology has the potential to increase the production of multiple lifesaving drugs and increase the economic efficiency and productivity in pharmaceutical manufacturing.